This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=108 http://www.lsis.com/goto/r108/rss 2012-02-05T11:11:09+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 Penzberg, Germany, January 31, 2012 / B3C newswire / - As of February 1, 2012, Dan Zabrowski is Head of Roche Applied Science in the Diagnostics Division, located in Penzberg, Germany. He succeeds Paul Brown who has led Roche Applied Science since September 2011. Dan Zabrowski will report to Daniel O Day, COO Roche Diagnostics. Dan recently served as Global Head of Roche Partnering and was a member of the Roche Corporate Executive Committee and Chugai Board. He joined Roche in 1994 through the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 Reno, Nevada and Branford, Connecticut, USA January 30, 2012 - Hamilton Robotics announced today a new automated solution for DNA sample enrichment on the MICROLAB STARlet Liquid Handling Workstation. Integrating Roche s REM e liquid handling system, the workflow solution enriches up to eight DNA samples for subsequent sequencing on the GS FLX System. The integrated system automates the multiple-step enrichment process, resulting in reduced variability, more consistent results and significant (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Proliferation of endothelial cells is critical for angiogenesis. We report orally available, in vivo active antiangiogenic agents which specifically inhibit endothelial cell proliferation. After identifying human umbilical vein endothelial cell (HUVEC) proliferation inhibitors from a cell-based high-throughput screening (HTS), we eliminated those compounds which showed cytotoxicity against HCT116 and vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitory activity. Evaluations in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Emphysematous cystitis is a rare disorder caused by bacterial infection and characterized by gas accumulation within the bladder wall with cyst formation. This report describes the histopathological characteristics of emphysematous cystitis found in a diabetic female beagle induced by streptozotocin and alloxan. Macroscopically, multiple cyst-like structures were observed on the cut surface of the urinary mucosa. During fixation, small specimens cut from the mucosa floated on the surface of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 The db/db mouse is one of the diabetes mellitus animal models and if the pathophysiological stages of diabetic changes in the mouse model could simulate the stages in human diabetes, the db/db mouse could be used to better evaluate drug candidates. Blood insulin, HbA1c levels and morphological features of pancreatic islets in db/db mice were evaluated to determine the pathophysiological stage. At 6 weeks of age, db/db mice showed the highest level of plasma insulin and lowest level of HbA1c, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 OBJECTIVE: To evaluate the safety and efficacy of ocrelizumab (OCR) in Japanese patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX). METHODS: RA patients with an inadequate response to MTX 6-8 mg/week received an infusion of 50, 200, or 500 mg OCR or placebo on Days 1 and 15 and were observed for 24 weeks. The double-blind period was prematurely terminated because of a possible risk for serious infection from OCR. RESULTS: A total of 152 patients were (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered an attractive therapeutic target for human cancers, especially non-small cell lung cancer (NSCLC). Our previous study revealed that 8,9-side-chains of 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole scaffold crucially affected kinase selectivity, cellular activity, and metabolic stability. In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been shown to have benefits for non-small cell lung cancer and pancreatic cancer patients; however, almost all patients develop progressive disease during the therapy. On the other hand, it has been reported that a tumor continues to express epidermal growth factor receptor even after developing progressive disease. To demonstrate the clinical relevance of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Macrocyclic compounds bearing a 2-amino-6-arylpyrimidine moiety were identified as potent heat shock protein 90 (Hsp90) inhibitors by modification of 2-amino-6-aryltriazine derivative (CH5015765). We employed a macrocyclic structure as a skeleton of new inhibitors to mimic the geldanamycin-Hsp90 interactions. Among the identified inhibitors, CH5164840 showed high binding affinity for N-terminal Hsp90? (K(d)=0.52nM) and strong anti-proliferative activity against human cancer cell lines (HCT116 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 SAN DIEGO, CA and VANCOUVER, Dec. 12, 2011 - Protox Therapeutics Inc. ("Protox", TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced the appointment of Dr. Richard Yocum as Chief Medical Officer, located in San Diego. Dr. Yocum joined Protox in November 2011 and brings 29 years of medical and drug development experience to the company. Before Protox he served as Vice President of Drug/Clinical Development and Medical Affairs at Rockwell (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 INDIANAPOLIS , Dec. 5, 2011 /PRNewswire/ - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a collaborative agreement with ChanTest Corporation, a leading ion channel screening provider, to perform cardiac safety testing of potential drug compounds using Roche's xCELLigence System RTCA Cardio Instrument and iCell Cardiomyocytes, human induced pluripotent stem (iPS) cell-derived cardiomyocytes provided by Cellular Dynamics International (CDI). Over the last two (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Coamplification of multiple segments of chromosome 2, including an MYCN-bearing segment, was examined in 2 cancer cell lines, NCI-H69 (lung cancer) and IMR-32 (neuroblastoma). High-resolution array-CGH analysis revealed 13 and 6 highly amplified segments located at different sites in chromosome 2 in NCI-H69 and IMR-32, respectively. FISH analysis demonstrated that these segments were co-localized in double minutes in NCI-H69 and in homogeneously staining regions in IMR-32. Connectivity of the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 We examined the efficacy of chemoendocrine therapy using capecitabine as a chemotherapeutic agent in premenopausal and postmenopausal models with estrogen receptor (ER)-positive human breast cancer xenografts. Tamoxifen and letrozole were used as endocrine therapeutic agents for premenopausal and postmenopausal models, respectively. The antitumor activity of capecitabine in combination was significantly superior to either monotherapy (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 LEXINGTON, Mass.-(BUSINESS WIRE)-Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech s new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib (GDC-0449, RG3616) is a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company s New Drug Application for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. The application has been granted Priority Review status and the FDA confirmed the action date is March 8, 2012. We hope to provide (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 CHICAGO-(BUSINESS WIRE)-Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from two large, Phase III clinical trials that assessed the efficacy and safety profile at 24 weeks in rheumatoid arthritis (RA) patients who received ACTEMRA (tocilizumab) as a monotherapy as well as those who received ACTEMRA plus a disease-modifying antirheumatic drug (DMARD), including methotrexate (MTX). These data will be presented as oral and poster presentations at the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Heat shock protein 90 (Hsp90), a molecular chaperone that plays a significant role in the stability and maturation of client proteins, including oncogenic targets for cell transformation, proliferation, and survival, is an attractive target for cancer therapy. We identified the novel Hsp90 inhibitor, CH5164840, and investigated its induction of oncogenic client protein degradation, antiproliferative activity, and apoptosis against an NCI-N87 gastric cancer cell line and a BT-474 breast cancer (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Eldecalcitol (ED-71) is a new vitamin D(3) derivative recently approved for the treatment of osteoporosis in Japan. Previous studies have shown that the daily administration of ED-71 increases bone mineral density (BMD) by suppressing bone resorption in various animal models. In this study, we examined how ED-71 suppresses bone resorption in vivo, by analyzing bone histomorphometry and ex vivo osteoclastogenesis assays. Daily administration of ED-71 (50 ng/kg body weight) to 8-week-old male (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Several clinical studies have demonstrated that the humanized anti-interleukin-6 (IL-6) receptor antibody tocilizumab (TCZ) improves clinical symptoms and prevents progression of joint destruction in rheumatoid arthritis (RA). However, the precise mechanism by which IL-6 blockade leads to the improvement of RA is not well understood. IL-6 promotes synovitis by inducing neovascularization, infiltration of inflammatory cells, and synovial hyperplasia. IL-6 causes bone resorption by inducing (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 INDIANAPOLIS & SAN DIEGO-(BUSINESS WIRE)-Roche Diagnostics U.S., with its business unit Roche Diabetes Care, a leader in blood glucose monitoring and insulin delivery systems, and DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring systems, announced today that they have signed a research and development agreement. The goal of this agreement is to integrate DexCom s next generation continuous glucose monitoring (CGM) system with the next generation of Accu-Chek insulin (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Eldecalcitol is a new vitamin D(3) derivative recently approved for the treatment of osteoporosis in Japan. Previous studies showed that daily administration of eldecalcitol increased bone mineral density (BMD) by suppressing bone resorption in animals and in patients with osteoporosis. We examined how eldecalcitol suppresses bone resorption in vivo . Daily administration of eldecalcitol into mice did not affect properties of osteoclast precursors, but suppressed RANKL expression in bone. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 IL (interleukin)-6, which was originally identified as a B-cell differentiation factor, is a multifunctional cytokine that regulates the immune response, haemopoiesis, the acute phase response and inflammation. IL-6 is produced by various types of cell and influences various cell types, and has multiple biological activities through its unique receptor system. IL-6 exerts its biological activities through two molecules: IL-6R (IL-6 receptor) and gp130. When IL-6 binds to mIL-6R (membrane-bound (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Cardiomyocytes derived from human induced pluripotent stem cells (hiPS-CMs) hold great promise for development of in vitro research tools to assess cardiotoxicity, including QT prolongation. In the present study, we aimed to clarify the electrophysiological/pharmacological characteristics of hiPS-CMs using the patch-clamp technique. The hiPS cells were differentiated into beating cardiomyocytes by the embryoid body method. The expression of genes related to cardiac ion channels and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Cancer Immunotherapy research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 27,000 individuals working in Cancer Immunotherapy. http:/bit.ly/qm59lO. Top 10 Countries for Cancer Immunotherapy Research (ranked by number of senior (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 A robust and sensitive method using liquid chromatography-tandem mass spectrometry was developed and validated for the simultaneous determination of a novel topoisomerase 1 inhibitor CH0793076 (3076), the prodrug CH4556300 (TP300), and the active metabolite CH0793011 (3011) in human plasma. All plasma analyzed with this method was acidified with 1M HCl and 46% citric acid solution in a ratio of 100:10:1 (v:v:v) to avoid the pH-based degradation of TP300 and to shift the equilibria of 3076 and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Bone Cancer research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 108,000 individuals working in Bone Cancer. http:/bit.ly/nc0nYl. Top 10 Countries for Bone Cancer Research (ranked by number of senior researchers): United States Of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 Rotkreuz, Switzerland / Asnieres, France - Roche Professional Diagnostics and Diagnostica Stago announced today that the companies have decided to pursue separate paths in the business of Laboratory Coagulation in the territories where Roche distributed the Stago product range. The exclusive sales of Stago products by Roche will continue throughout the entire year of 2011.With the exception of Japan where Roche Diagnostics Japan will continue to distribute the Stago portfolio within the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 (Oxford UK and Philadelphia, US) 19th September 2011. Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune s Chief Operating Officer, becomes an executive director. Adaptimmune is strengthening its Board following the opening of three pilot (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc today announced that Dr. Andrew von Eschenbach and Mr. Hans Peter Hasler have become non-executive members of Elan s board of directors and Mr. Shane Cooke has retired as an executive director. Elan's Chairman, Robert Ingram commented œWe are pleased to welcome Dr. von Eschenbach and Mr. Hasler to the board of directors of Elan. Both individuals possess exceptional professional backgrounds, the highest degree of integrity and strength in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 Penzberg, Germany, September 15, 2011 / B3C newswire / - Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug discovery process. In a new research study (1), Abassi et al. investigated the use of Roche s (SIX: RO, ROG; OTCQX: RHHBY) xCELLigence Cardio Instrument in conjunction with embryonic stem cell derived cardiomyocytes (ESCC) for assessment of compound risk in the drug discovery (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 PURPOSE: CYP3A4 and P-glycoprotein (P-gp) are present in the human intestine and mediate intestinal first-pass metabolism and the efflux of oral drugs, respectively. We aimed to predict whether intestinal CYP3A4/P-gp is saturated in a therapeutic dose range. METHODS: Information on the Michaelis-Menten constant (Km), product of the fraction absorbed (Fa) and intestinal availability (Fg) (FaFg) of CYP3A4/P-gp substrates, and clinical AUC data including two or more different dosages for each (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 LEXINGTON, Mass.-(BUSINESS WIRE)-Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib (GDC-0449, RG3616) to treat people with advanced basal cell carcinoma (BCC), which includes (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=108 Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, "Chugai")] announced that it has entered into license agreements with F. Hoffmann-La Roche, Ltd [Head Office: Basel, Switzerland / CEO: Severin Schwan (hereafter, "Roche")] covering humanized anti-Met antibody MetMAb, for non-small cell lung cancer (NSCLC) and humanized anti-interleukin(IL)-13 antibody lebrikizumab for bronchial asthma which are both currently developed by Roche utilizing the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Heat shock protein 90 (Hsp90) is a molecular chaperone which regulates maturation and stabilization of its substrate proteins, known as client proteins. Many client proteins of Hsp90 are involved in tumor progression and survival and therefore Hsp90 can be a good target for developing anticancer drugs. With the aim of efficiently identifying a new class of orally available inhibitors of the ATP binding site of this protein, we conducted fragment screening and virtual screening in parallel (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 Madison, WI, USA, September 6, 2011 / B3C newswire / - The Genetic Laboratory of the Department of Internal Medicine at Erasmus University Medical Centre in Rotterdam has adopted the combined automated target enrichment solution from Roche (SIX: RO, ROG; OTCQX: RHHBY) and Caliper Life Sciences. This optimized solution is being used in a new phase of a large human epidemiological cohort, the Rotterdam Study, for automating the capture of 3,000 samples for next-generation sequencing. The (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 Penzberg, Germany, September 1, 2011 / B3C newswire / - A vast majority of biotherapeutics are manufactured in either bacterial or mammalian expression systems. Metabolite profiling and substrate analysis during the fermentation process is critical to ensure optimal conditions for production and will trigger actions such as feed, improvement of oxygenation, adjustment of pH etc. The new Cedex Bio Bioprocess Analyzer from Roche (SIX: RO, ROG; OTCQX: RHHBY) is a continuous random-access (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 5a-Carba-?-d-glucopyranose derivatives were synthesized and identified as novel SGLT2-selective inhibitors. These inhibitors exhibited potent SGLT2 inhibition with high selectivity over SGLT1. Among the tested compounds, 6f indicated the most potent hSGLT2 inhibition and the highest selectivity over hSGLT1. Moreover, the pharmacokinetics data also showed that 6h, which had the same aglycon structure as sergliflozin-active (3-active), had a threefold longer half-life time (T(1/2) than (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 MADISON, Wis.-(BUSINESS WIRE)-In May 2011, The University of Iowa, Roy J. Carver Center for Genomics (CCG), entered into an agreement with Roche NimbleGen to provide microarray services through the Roche NimbleGen Certified Service Provider (CSP) program. In July 2011, after passing their rigorous certification test plan, CCG received official certification as a Roche NimbleGen CSP for two microarray applications: array Comparative Genomic Hybridization (CGH) and gene expression. "As a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 BRANFORD, Conn.-(BUSINESS WIRE)-Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, representing two strains of the therapeutic plant. The genome assemblies, comprising over 131 billion bases of sequence, are the largest known gene collection of the Cannabis genomes and will be made publically available to the scientific community this fall. The (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Antigen Antibody Reactions database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 54,000 individuals working in Antigen Antibody Reactions. http:/bit.ly/p4Zlgl. Top 10 Countries for Antigen Antibody Reactions (ranked by number of senior (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=108 MADISON, Wis. & WALTHAM, Mass.-(BUSINESS WIRE)- Roche (SIX: RO, ROG; OTCQX: RHHBY) and PerkinElmer (NYSE:PKI - News) today announced a new supply agreement for distribution of the NimbleGen CGX microarray workflow, for use in constitutional disease research. Under this agreement, effective January 2012, PerkinElmer will assume responsibility from Roche for sales, service, and support of the CGX array workflow for most countries outside of the U.S. Roche will continue to sell this innovative (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 BRANFORD, Conn.-(BUSINESS WIRE)-In a study published online this week in Nature, an international team of researchers report the first complete sequence of the Atlantic cod genome and an unexpected discovery of the unique immune system of this important fish species. Led by researchers from the University of Oslo, a consortium of Norwegian universities and aquaculture institutions turned to 454 Sequencing Systems from Roche (SIX: RO, ROG; OTCQX: RHHBY) to obtain a comprehensive de novo (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Drug Transporter Assays database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 15,000 individuals working in Drug Transporter Assays. http:/bit.ly/qpShGp. Top 10 Countries for Drug Transporter Assay Research (Ranked by Number of Senior (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Antibody Production database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 113,000 individuals working in Antibody Production. http:/bit.ly/o5T3p3. Top 10 Countries for Antibody Production (Ranked by Number of Senior Researchers): United States Of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Cell Surface Antigens database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 72,000 individuals working in Cell Surface Antigens. http:/bit.ly/r4CIw5. Top 10 Countries for Cell Surface Antigens (Ranked by Number of Senior Researchers) United (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=108 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Clinical Toxicology research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 23,000 individuals working in Clinical Toxicology. http:/bit.ly/nvZJUi. Top 10 Countries for Clinical Toxicology Research (ranked by number of senior researchers) (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 The G2 checkpoint is an indispensable pathway for cancers lacking p53 function, for delaying cell cycle progression, and for completing DNA repair. Therefore, disruption of this pathway is expected to offer selective therapy for these highly prevalent cancers. The aim of this study was to identify an inhibitor of the G2 checkpoint including the ataxia-telangiectasia-mutated and Rad3-related checkpoint kinase 1 pathway that selectively suppresses the growth of p53-deficient cells. To obtain (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Capecitabine is an oral anticancer prodrug which is converted to 5-fluorouracil (5-FU) via 3 enzymatic steps, these being 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR), and finally 5-FU by carboxylesterase (CES), cytidine deaminase (CDA), and thymidine phosphorylase (TP), respectively. Because rats, mice and monkeys are used for preclinical safety studies, we investigated the in vitro conversion from capecitabine to 5-FU by hepatic and intestinal mucosal microsomes (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=108 Novel vitamin D(3) analogs with carboxylic acid were explored, focusing on a nonsecosteroidal analog, LG190178, with a bisphenyl skeleton. From X-ray analysis of these analogs with vitamin D receptor (VDR), the carboxyl groups had very unique hydrogen bonding interactions in VDR and mimicked 1?-hydroxy group and/or 3?-hydroxy group of 1?,25-dihydroxyvitamin D(3). A highly potent analog, 6a, with good in vitro activity and pharmacokinetic profiles was identified from an SAR study. Compound (…)